Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.7%

5 terminated/withdrawn out of 22 trials

Success Rate

64.3%

-22.2% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

122%

11 of 9 completed trials have results

Key Signals

7 recruiting11 with results

Enrollment Performance

Analytics

Phase 2

9(47.4%)

Phase 1

6(31.6%)

N/A

4(21.1%)

19Total

Phase 2(9)

Phase 1(6)

N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials

NCT02559778Phase 2Recruiting

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

Role: lead

NCT04696029Phase 2Recruiting

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Role: lead

NCT06540963Phase 2Recruiting

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Role: lead

NCT03581240Unknown

An Intermediate Expanded Use Trial of DFMO

Role: lead

NCT04715178Recruiting

Beat Childhood Cancer Specimen Banking and Data Registry

Role: lead

NCT05489887Phase 2Recruiting

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Role: lead

NCT04301843Phase 2Recruiting

Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Role: lead

NCT02679144Phase 2Recruiting

Neuroblastoma Maintenance Therapy Trial

Role: lead

NCT02162732Not ApplicableCompleted

Molecular-Guided Therapy for Childhood Cancer

Role: lead

NCT01059071Phase 1Completed

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Role: lead

NCT01483820Phase 1Terminated

Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Role: lead

NCT02630043Phase 1Terminated

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

Role: lead

NCT00601003Phase 2Completed

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Role: lead

NCT01355679Not ApplicableCompleted

Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma

Role: lead

NCT01802567Not ApplicableCompleted

Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer

Role: lead

NCT01109238Completed

A Trial Using Molecular-Guided Therapy in Patients With Refractory or Recurrent Neuroblastoma

Role: lead

NCT02139397Phase 1Completed

Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

Role: lead

NCT01505608Phase 1Terminated

Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Role: lead

NCT00867568Phase 1Completed

TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma

Role: lead

NCT01774253Phase 2Terminated

Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma

Role: lead